Michael Brehm to Rituximab
This is a "connection" page, showing publications Michael Brehm has written about Rituximab.
Connection Strength
0.139
-
Megathlin HR, Burzenski L, Brehm MA, Greiner DL, Balu-Iyer S, Shultz LD. Increased longevity of circulating human IgG in an NSG Fc gamma receptor-1 deficient humanized mouse model. J Pharm Sci. 2025 Oct; 114(10):103964.
Score: 0.058
-
Saikumar Lakshmi P, Oduor CI, Forconi CS, M'Bana V, Bly C, Gerstein RM, Otieno JA, Ong'echa JM, M?nz C, Luftig MA, Brehm MA, Bailey JA, Moormann AM. Endemic Burkitt lymphoma avatar mouse models for exploring inter-patient tumor variation and testing targeted therapies. Life Sci Alliance. 2023 05; 6(5).
Score: 0.049
-
Verma MK, Clemens J, Burzenski L, Sampson SB, Brehm MA, Greiner DL, Shultz LD. A novel hemolytic complement-sufficient NSG mouse model supports studies of complement-mediated antitumor activity in vivo. J Immunol Methods. 2017 07; 446:47-53.
Score: 0.032